Enteral feeding is a very useful method of ensuring adequate intake of fluid and nutrients in patients who, for a variety of reasons, are unable to use the oral route, or are unable to take sufficient nutrients to maintain growth and development.
A gastrostomy is a feeding tube that is inserted directly into the stomach either surgically under direct vision (open or laproscopic), endoscopically (with a camera), or radiologically (x-ray guidance). A gastrostomy tube allows the delivery of supplemental nutrition and medications directly into the stomach. It also provides a mechanism to drain gastric contents if required. In order for gastrostomy feeding to be successful the child or young person must have a functioning gastrointestinal tract.
The purpose of this clinical guideline is to support staff with the recognition, prevention and treatment of refeeding syndrome in children and young people who have experienced a period of insufficient nutrition.
This guideline describes the procedure which must be followed whenever a diagnosis of Mycobacterium Tuberculosis (M.TB) infection is suspected or confirmed, to optimally protect staff, patients and other visitors from risk of infection and assist in the care of the child with M.TB (not including Occupational Health policy).
This guideline is intended to guide and facilitate the care of patients under the care of the clinical teams at Great Ormond Street Hospital for Children NHS Trust (GOSH). It has been approved by the Guideline Approval Group and is for use by staff of all disciplines and levels in these health care teams. The guidance contained here in is not intended to replace individual assessment and personalised treatment of the patient.
This clinical guideline from Great Ormond Street Hospital (GOSH) discusses nutritional requirements for preterm infants receiving enteral nutrition. It does not give guidance on the prescription of parenteral nutrition (PN).
The ketogenic diet (KD) is a therapeutic diet, which has been shown to improve seizure control in patients with drug resistant epilepsy, and is used in some patients with metabolic conditions for example, glucose transporter type 1 deficiency syndrome (GLUT1) and pyruvate dehydrogenase deficiency (PDH).